概括
与glibenclamide相比, хлорпропамид在治疗饮食失败的糖尿病方面表现出更好的长期有效性,治疗失败的次数更少,低血糖的严重程度更小. 格利本克拉米德显示,低血糖事件的发生率更高.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 硫尿素是治疗2型糖尿病的基石.
- Glibenclamide 和 chlorpropamide 是通常被处方的口服低血糖剂.
- 对于这些药物在特定糖尿病人群中的长期比较有效性数据至关重要.
研究的目的:
- 为了比较glibenclamide与公胺的长期临床疗效.
- 为了评估治疗失败率和患者在两年内坚持治疗.
- 评估低血糖事件的发生率和严重程度.
主要方法:
- 一项涉及321名新诊断的,饮食失败的,非肥胖的,成熟期糖尿病患者的比较研究.
- 患者接受了用glibenclamide或chlorpropamide的治疗.
- 临床有效性通过治疗失败率,患者保留率,血糖水平,体重变化和两年内的低血糖发作来评估.
主要成果:
- 与glibenclamide相比,公胺的初级失效率明显较低 (p<0.05).
- 在两年后,更大比例的患者仍在服用propamide (p<0.01).
- 低血糖发作更频繁,更严重的glibenclamide;二次失败的差异没有统计学意义. 血糖和体重的变化是可比的.
结论:
- хлорпропамид似乎比glibenclamide更有效的长期管理饮食失败的2型糖尿病.
- Glibenclamide 与高血糖降低的风险有关.
- 这些发现支持在临床实践中仔细考虑选择硫基尿素.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
